bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD DisclosureItem 7.01
Regulation FD Disclosure
bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD Disclosure
On September 13, 2017, bluebird bio, Inc. (“bluebird”) issued a press release announcing the initiation of the expansion cohort of CRB-401, the Phase 1 study for bluebird’s anti-BCMA CAR T cell therapy partnered with Celgene Corporation. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 7.01Financial Statements and Exhibits.
(d) Exhibits
bluebird bio, Inc. ExhibitEX-99.1 2 blue-ex991_17.htm EX-99.1 blue-ex991_17.htm Exhibit 99.1 bluebird bio Announces First Patient Treated in Expansion Cohort of CRB-401,…To view the full exhibit click here
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
